B-Cell CLL/lymphoma 2 (BCL2) antibody
|Synonyms||Bcl-2, bcl-2, BCL2|
Alternatives Western Blotting (WB), Flow Cytometry (FACS), Fluorescence Microscopy (FM), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunoprecipitation (IP)
|10 references available|
|Quantity||0.1 mg (0.5 mg/ml)|
|Price||Product not available in this region.|
|Immunogen||Recombinant Mouse Bcl-2|
|Description||Bcl-2 is considered to be novel among proto-oncogenes because it blocks apoptosis (programmed cell death) in many cell types. Apoptosis is an active form of cellular suicide that typically requires new RNA and protein synthesis and is associated with distinct morphological changes including cell shrinkage, cytoplasm membrane blebbing, nuclear fragmentation and DNA degradation. The Bcl-2 gene was first found in t(14:18) containing follicular B-cell lymphomas. A high proportion of these lymphomas contain t(14:18) chromosomal translocations involving the human Bcl-2 gene. Translocation of Bcl-2 sequences from chromosome 18 onto the transcriptionally active immunoglobulin locus at chromosome band 14q32 in B-cells deregulates Bcl-2 gene expression, resulting in high levels of Bcl-2 mRNA and protein expression. Because Bcl-2 blocks apoptosis it may contribute to tumorigenisis by prolonging cell survival rather than by accelerating the rate of cell proliferation. Mouse Bcl-2 migrates at a reduced molecular weight of ~26 kD. This antibody recognizes a 26 kD band representing the mouse p26-Bcl-2 protein. Additional minor bands at 27-31 kD and 18-21 kD may be visualized. The 27-31 kD upper band may represent a larger isoform, whereas the 18-21 kD lower band may be an internal translation or proteolytic product. 3F11 does not cross-react with human Bcl-2. For detection of human Bcl-2, refer to clone 6C8 (ABIN967311), or clone 4D7.|
1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Although hamster immunoglobulin isotypes have not been well defined, BD Biosciences Pharmingen has grouped Armenian and Syrian hamster IgG monoclonal antibodies according to their reactivity with a panel of mouse anti-hamster IgG mAbs.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
4. Please refer to us for technical protocols.
|Molecular Weight||26 kDa|
Related Products: ABIN967311
|Application Notes||Reported ranges for usage in western blot and IHC on frozen sections, is around 5 µg/ml. The antibody should be titrated for each application. Thymus and M1 mouse myeloma cells (ATCC TIB-192) are suggested as positive controls. For immunofluroescent staining and flow cytometry, the directly conjugated formats of this clone are recommended (Cat No. 554221 and 556537).|
|Purification||Purified from tissue culture supernatant or ascites by affinity chromatography.|
|Buffer||Aqueous buffered solution.|
|Preservative||0.09% Sodium azide.|
|Storage||Store undiluted at 4°C.|
|Research Area||Cancer, Apoptosis/Necrosis|
|Restrictions||For Research Use only|
Williams: "Programmed cell death: apoptosis and oncogenesis." in: Cell, Vol. 65, Issue 7, pp. 1097-8, 1991 (PubMed).
Hockenbery, Nuñez, Milliman et al.: "Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death." in: Nature, Vol. 348, Issue 6299, pp. 334-6, 1991 (PubMed).
Reed, Tsujimoto, Alpers et al.: "Regulation of bcl-2 proto-oncogene expression during normal human lymphocyte proliferation." in: Science (New York, N.Y.), Vol. 236, Issue 4806, pp. 1295-9, 1987 (PubMed).
Tsujimoto, Cossman, Jaffe et al.: "Involvement of the bcl-2 gene in human follicular lymphoma." in: Science (New York, N.Y.), Vol. 228, Issue 4706, pp. 1440-3, 1985 (PubMed).
Novack, Korsmeyer: "Bcl-2 protein expression during murine development." in: The American journal of pathology, Vol. 145, Issue 1, pp. 61-73, 1994 (PubMed).
Miyashita, Krajewski, Krajewska et al.: "Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo." in: Oncogene, Vol. 9, Issue 6, pp. 1799-805, 1994 (PubMed).
Oltvai, Milliman, Korsmeyer: "Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death." in: Cell, Vol. 74, Issue 4, pp. 609-19, 1993 (PubMed).
Veis, Sentman, Bach et al.: "Expression of the Bcl-2 protein in murine and human thymocytes and in peripheral T lymphocytes." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 151, Issue 5, pp. 2546-54, 1993 (PubMed).
Krajewski, Tanaka, Takayama et al.: "Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes." in: Cancer research, Vol. 53, Issue 19, pp. 4701-14, 1993 (PubMed).
Veis, Sorenson, Shutter et al.: "Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair." in: Cell, Vol. 75, Issue 2, pp. 229-40, 1993 (PubMed).